CLDN3 and breast carcinoma: In vitro data supports these results, since siRNA treatment against claudin 3 in metastatic breast cancer cells has been reported to attenuate cellular motility, and higher intracellular claudin 3 expression was connected to tight-junction disruption and local invasiveness.